OVERVIEW

The American Academy of Orthopaedic Surgeons (AAOS), in collaboration with the Musculoskeletal Tumor Society (MSTS), announced the launch of a Musculoskeletal Tumor Registry (MsTR) feasibility pilot in December 2018. The goal of the pilot was to begin capturing data on orthopaedic oncology, bone tumor procedures in a structured and scalable way. The decision was made to broaden the MsTR program from a pilot to a full registry at the end of 2019. The Musculoskeletal Tumor Registry is the third subspecialty registry to be incorporated into the AAOS family of registries.

The wide-spread rollout of the MsT Registry allows surgeons to combine data about rare bone and soft tissue tumors from institutions around the country, thereby potentially answering treatment and outcome questions that are otherwise unable to be answered due to the rarity of the disease. The MsTR feedback and dashboards will help clinicians and health systems track function, complications, and outcomes in patients treated for these sarcomas with the potential to expand to other musculoskeletal tumors and metastatic bone diseases in the future.

STEERING COMMITTEE

- **Benjamin Miller, MD, FAAOS, MS, Chair**
  University of Iowa Hospital and Clinics
- **John Alexander Abraham, MD, FAAOS**
  Rothman Orthopaedic Institute
- **Megan E. Anderson, MD, FAAOS**
  Boston Children’s Hospital
  Dana-Farber Cancer Institute
- **George T Calvert, MD, FAAOS**
  Norton Healthcare
- **Eric Henderson, MD, FAAOS**
  Dartmouth-Hitchcock Medical Center
- **Adam Levin, MD, FAAOS**
  Johns Hopkins Medicine
- **Nathan Mesko, MD, FAAOS**
  Cleveland Clinic Foundation
- **Peter Rose, MD, FAAOS**
  Mayo Clinic
- **Mark Scarborough, MD, FAAOS**
  University of Florida
- **Kristy L Weber, MD, FAAOS**
  University of Pennsylvania

GET STARTED

Organizations interested in participating in the MsT Registry can contact RegistryEngagement@aaos.org.
DATA ELEMENT OVERVIEW

Data elements will include but are not limited to patient demographics, patient baseline and examination, tumor baseline, treatment and post-treatment, and surgery detail along with postoperative data (oncologic failure, surgery complication, vital status), and patient-reported outcomes as conveyed in applicable instruments. This page is a summary of the MsTR data elements and is not all inclusive.

BASELINE

Patient
- Name (Last, First)
- Date of Birth
- Social Security Number
- Diagnosis (ICD-10, CPT)
- Gender
- Race/Ethnicity
- Height + Weight/Body Mass Index
- Payer Status

Site of Service
- Name and Address (TIN, NPI)

Surgeon
- Name (NPI)

Surgical Intervention
- Procedure Type (ICD-10, CPT)
- Date of Surgery
- Implants
- Details Surrounding Surgery Type
- Comorbidities (ICD-10, CPT)

Non-Surgical Intervention
- Chemotherapy
- Radiation
- Clinical Trial

Tumor Baseline
- Size
- Metastasis at Diagnosis
- Margins
- Tissue Type
- Biopsy Type

ENCOUNTERS AND PATIENT-REPORTED OUTCOMES

Encounters
- Comorbidities (ICD-10, CPT)
- Hospital Admission
- Procedure (ICD-10, CPT)
- Diagnosis (ICD-10, CPT)
- Recurrence
- Chemotherapy
- Radiation

Patient-reported Outcomes
- PROMIS-10 Global
- VR-12
- MSTS
- TESS

Get Started Today by Enrolling Here